VANCOUVER, British Columbia, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with the Chamber of Commerce, Industry, Services and Tourism Brazil & Puerto Rico (“C2BPR”) with the aim of helping to commence, maintain, and expand businesses in the medical cannabis sector for the Brazil and Puerto Rico markets.
Under the terms of the MOU, both parties will advise each other of events that may impact its mission; suggest speakers to participate in workshops, conferences, seminars and other related events. Both parties will also discuss bilateral trade between Veritas & C2BPR and other commercial topics; provide each other with information on business opportunities that may become available to Veritas about the Brazilian & Puerto Rican markets; and lastly support each other, as long as possible, in coordinating and promoting related seminars and conferences.
For more information about C2BPR, please visit their website at: www.c2bpr.com
Veritas Pharma’s CEO, Dr. Lui Franciosi, stated, “We are delighted to work with C2BPR on addressing business communities in Brazil and Puerto Rico where the focus is opening up markets for scientifically-based medical cannabis products.” By sharing its knowledge and experience of medical cannabis from its bases in Puerto Rico and Canada, Veritas Pharma aims to educate all stakeholders, particularly, in Brazil about the pharmacological evaluation and the therapeutic value of cannabis products such as the Company’s Cannevert brand.
The Company also announces the issuance of 500,000 stock options at $0.22 to a consultant of the Company for a term of twelve (12) months.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.
Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors
"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.